Hikma Pharmaceuticals Financials
| HKMPY Stock | USD 49.81 0.70 1.39% |
Hikma |
Understanding current and past Hikma Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Hikma Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Hikma Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Hikma Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Hikma Pharmaceuticals PLC. Check Hikma Pharmaceuticals' Beneish M Score to see the likelihood of Hikma Pharmaceuticals' management manipulating its earnings.
Hikma Pharmaceuticals Stock Summary
Hikma Pharmaceuticals competes with Viatris, Catalent, Bausch Health, and Tilray. Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company was founded in 1978 and is based in London, the United Kingdom. Hikma Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 8700 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US4312881091 |
| Business Address | 1 New Burlington |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Benchmark | Dow Jones Industrial |
| Website | www.hikma.com |
| Phone | 44 20 7399 2760 |
| Currency | USD - US Dollar |
Hikma Pharmaceuticals Key Financial Ratios
Hikma Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Hikma Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Hikma Pharmaceuticals over time and compare it to other companies across industries.| Return On Equity | 0.15 | |||
| Return On Asset | 0.077 | |||
| Beta | 0.35 | |||
| Z Score | 4.2 | |||
| Last Dividend Paid | 0.55 |
Hikma Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Hikma Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Hikma Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Hikma Pharmaceuticals competition to find correlations between indicators driving Hikma Pharmaceuticals's intrinsic value. More Info.Hikma Pharmaceuticals PLC is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers reporting about 0.50 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Hikma Pharmaceuticals PLC is roughly 2.00 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Hikma Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Hikma Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Hikma Pharmaceuticals PLC Systematic Risk
Hikma Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Hikma Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourty-two with a total number of output elements of nineteen. The Beta measures systematic risk based on how returns on Hikma Pharmaceuticals PLC correlated with the market. If Beta is less than 0 Hikma Pharmaceuticals generally moves in the opposite direction as compared to the market. If Hikma Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Hikma Pharmaceuticals PLC is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Hikma Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Hikma Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Hikma Pharmaceuticals December 12, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Hikma Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Hikma Pharmaceuticals PLC. We use our internally-developed statistical techniques to arrive at the intrinsic value of Hikma Pharmaceuticals PLC based on widely used predictive technical indicators. In general, we focus on analyzing Hikma Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Hikma Pharmaceuticals's daily price indicators and compare them against related drivers.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 10.6 | |||
| Value At Risk | (3.53) | |||
| Potential Upside | 2.5 |
Additional Tools for Hikma Pink Sheet Analysis
When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.